Cabaletta Bio expects to complete $35M stock and warrant sale this week to advance cell therapy candidate


The company's lead cell therapy candidate is being developed to treat multiple autoimmune diseases.

Previous Durham drugmaker to cut workforce by 25%, focus on new cancer drug
Next Meridian Bioscience sets closing date for $1.53 billion deal